IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers. DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites. Five hundred six adult (Ն18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study. INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence. Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52. Outcomes were biochemically confirmed.RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively). At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively). At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively). Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks. Neither outcome was significantly different at 52 weeks. Further research is required to determine the role of combination therapy in smoking cessation.
The efficacy of nicotine patch therapy has been demonstrated in numerous placebocontrolled trials'-8 and supported by metaanalyses9-'2 and studies of general populations.'3"4 Nicotine patch therapy generally doubles abstinence rates over placebo controls at both short-term (end of patch therapy) and long-term (6 to 12 months) follow-ups.2-8Although safety concems were raised shortly after the introduction ofthe nicotine patch, 15"6 controlled trials2-8 and population survey studies' 134 have not raised any serious safety concerns about nicotine patch therapy. Recent clinical practice guidelines published by the Agency for Health Care Policy and Research recommended the use ofnicotine replacement in smoking cessation by most patients.17Despite the proven efficacy and safety ofnicotine patch therapy, there are significant barriers to its widespread use among smokers.Two substantial barriers to wider use of nicotine patch therapy have been cost and the requirement for a physician's prescription. The requirement for a prescription not only represented an obstacle but also added to the cost of using nicotine patch therapy. It was believed that removing the prescription barrier could encourage more smokers to try to stop smoking by using nicotine patch treatment. Because of this and the demonstrated efficacy and safety of nicotine patch therapy in clinical trials, nicotine patches were released for overthe-counter purchase in 1996.In our 1994 to 1995 study, we attempted to replicate the over-the-counter environment while maintaining regular contact with study subjects to observe and scientifically validate their response to therapy. Our specific aims were to (1) determine the efficacy of 22-mg, 24-hour nicotine patch therapy in an overthe-counter environment for smokers interested in stopping smoking and (2) determine the safety ofnicotine patch therapy when it is used in an over-the-counter setting. MethodsOverview A true simulation of an over-the-counter environment requires that subjects pay for their medication. This causes a dilemma for investigators who wish to perform a placebocontrolled trial in an over-the-counter environment, because it would be unethical to ask volunteer subjects to pay for placebo. In an attempt to overcome this difficulty, we performed 2 parallel over-the-counter smoking cessation trials: a double-blind, placebo-controlled trial of placebo vs 22-mg, 24-hour patch (patches were provided free of charge) and an open label trial of active 22-mg, 24-hour patch therapy in which subjects paid for nicotine patches. (Nicotine patches were supplied by Elan Pharmaceutical Technologies, Athlone, Ireland.) Inclusion and exclusion criteria were identical for both trials, and except for the use of placebo patches in the former trial, all study methods were identical. In this article, the former trial is referred to as the placebo-controlled trial and the latter is referred to as the open label-pay trial. ParticipantsSubjects were recruited, via media advertisements, for participation in a smoking ces-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.